Last Updated: November 16, 2026

Details for Patent: 9,585,868

« Back to Dashboard


Which drugs does patent 9,585,868 protect, and when does it expire?

Patent 9,585,868 protects MYTESI and is included in one NDA.

This patent has twenty-seven patent family members in twenty-one countries.

Summary for Patent: 9,585,868
Title:Methods and compositions for treating HIV-associated diarrhea
Abstract:Presented herein are methods for treating diarrhea by administering to a patient in need thereof, an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea. Treatment of diarrhea includes the treatment of the diarrhea as well as the pain, abdominal discomfort and other symptoms associated with diarrhea. In one embodiment, the inhibitor of chloride-ion transport is crofelemer.
Inventor(s):William Forbes, Enoch Bortey, Steven King, Pravin Chaturvedi
Assignee: Salix Pharmaceuticals Inc , Napo Pharmaceuticals Inc
Application Number:US14/597,740
Patent Claim Types:
see list of patent claims
Use;
Patent landscape, scope, and claims:

United States Drug Patent 9,585,868: Crofelemer Claims, Exclusivity, Litigation Risk, and Patent Landscape

U.S. Patent No. 9,585,868 protects a specific method of using crofelemer, marketed as Mytesi, to treat HIV-associated or HAART-associated diarrhea. The principal claim requires an HIV-positive patient, a daily dose of approximately 250 mg or 125 mg twice daily, and treatment directed to ameliorating diarrhea symptoms. The patent does not broadly claim crofelemer, all diarrhea indications, or every dosage form.

The strongest commercial coverage is the combination of indication, patient population, and dose. The principal design-around paths are to challenge those limitations, use a different dose or regimen, target a non-HIV indication, or contest the patent's validity and enforceability.

What does U.S. Patent 9,585,868 protect?

U.S. Patent 9,585,868 protects methods for administering crofelemer to HIV-positive patients with HIV-associated diarrhea or HAART-associated diarrhea. Claim 1 is the broadest independent claim:

Claim element Required limitation
Active ingredient Crofelemer
Patient HIV-positive subject
Condition HIV-associated diarrhea or HAART-associated diarrhea
Dose About 250 mg per day or about 125 mg twice per day
Purpose Ameliorating symptoms

The patent is a method-of-treatment patent, not a composition-of-matter patent. It does not claim the molecular structure of crofelemer or crofelemer generally as a pharmaceutical ingredient.

The patent was granted on March 7, 2017. The listed assignee is Napo Pharmaceuticals, Inc., the developer associated with crofelemer and Mytesi.[1]

How broad is independent claim 1?

Claim 1 is narrower than a general crofelemer diarrhea claim but commercially meaningful because it tracks the approved HIV-associated diarrhea use and the standard Mytesi dosing regimen.

Patient limitation

The patient must be HIV-positive. A patient with chronic noninfectious diarrhea, irritable bowel syndrome, cancer-treatment-associated diarrhea, or another unrelated condition would not fall within the express patient limitation of claim 1.

The claim does not expressly require:

  • A particular HIV viral load
  • A particular CD4 count
  • Active HAART use
  • A specific antiretroviral product
  • Failure of another antidiarrheal
  • A defined severity of diarrhea
  • A particular route of administration

Claim 20 adds a narrower patient history requirement: the HIV-positive patient must have previously used protease inhibitors.

Indication limitation

The claimed diarrhea must be HIV-associated or HAART-associated. This language creates an important causation and diagnosis issue. A generic manufacturer or prescriber could contest whether the diarrhea is caused by HIV infection, antiretroviral therapy, another medicine, an opportunistic infection, diet, or an unrelated gastrointestinal condition.

The patent does not claim all uses of crofelemer for diarrhea. Its scope is tied to the HIV and HAART populations identified in the claims.

Dose limitation

Claim 1 covers either:

  • Approximately 250 mg per day; or
  • Approximately 125 mg twice per day.

The word "about" provides some numerical flexibility, but it does not eliminate the dose limitation. A materially different daily dose may avoid literal infringement, although the doctrine of equivalents could create residual risk depending on the facts.

The claim also does not expressly require tablets, capsules, a particular excipient system, or a particular release profile. A product supplied in a different dosage form could still infringe if it is used in the claimed manner.

What do the dependent claims add?

Claims 2 through 19 add treatment-duration, response, symptom, and patient-profile limitations. They do not expand claim 1. Each is narrower than the claim from which it depends.

Claims Added subject matter Commercial effect
2 Treatment for about one to six months Supports medium-term treatment
3 Treatment for about three days to six months Covers early and medium-term use
4 Improvement begins on day 3 Adds a response-timing limitation
5 Improvement increases with longer treatment after day 3 Adds a longitudinal response limitation
6 Treatment for at least eight days Establishes a minimum duration
7 Treatment from eight days to 24 weeks Defines a bounded treatment period
8 Treatment for about six months Covers a six-month regimen
9 Treatment for about six months or longer Covers chronic treatment
10 Treatment for the duration of HIV infection Broadens duration within the dependent claim
11 Response increases after more than four months Adds a late-response limitation
12 Specific symptom improvements Creates an objective symptom list
13-14 Improved stool consistency and formed stools Focuses on stool quality
15-16 Reduced watery bowel movements or total bowel movements Defines treatment response
17 Measurement from baseline Adds a measurement framework
18 Reduced days per week of fecal incontinence Covers a specific patient outcome
19 Male patient Narrows the patient population

Claims 2, 3, 6, 7, 8, and 9 overlap substantially. That overlap is common in pharmaceutical method patents because different duration limitations preserve fallback positions if a broader claim is challenged.

What symptoms are covered by Patent 9,585,868?

Claim 12 identifies the principal symptom endpoints:

  • Fewer bowel movements per day
  • Fewer watery bowel movements per day
  • Better abdominal pain or discomfort scores
  • Better daily stool-consistency scores
  • Conversion from watery to formed stools
  • Fewer days per week with urgency
  • Fewer days per week with fecal incontinence
  • Fewer unscheduled visits caused by significant worsening of diarrhea

Claims 13 through 18 narrow these endpoints. The patent therefore covers more than a reduction in stool frequency. A treatment response based primarily on stool consistency, urgency, or fecal incontinence may fall within the dependent claims if the other claim 1 requirements are satisfied.

The use of "baseline" in claim 17 indicates that symptom improvement is measured against the patient's pre-treatment condition. The claims do not, on their face, establish a single numerical threshold for every symptom endpoint.

What is the scope of claim 20 for prior protease-inhibitor users?

Claim 20 covers the same crofelemer dose and HIV-associated or HAART-associated diarrhea indication as claim 1, but requires that the patient previously used protease inhibitors.

This claim has two effects:

  1. It narrows the patient population to a historically important HAART-treated group.
  2. It may provide a fallback claim if broader claim 1 is found vulnerable.

Claim 20 does not appear to require that the patient currently use a protease inhibitor. The stated requirement is prior use. It also does not limit the claim to one protease inhibitor, one treatment duration, or one level of treatment failure.

When does U.S. Patent 9,585,868 expire?

The patent issued in 2017, but patent expiration is generally calculated from the relevant nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other USPTO events. The patent's expected term runs into 2029 based on its priority and filing history.[1][2]

The legally operative expiration date should be determined from the USPTO Patent Center record and any Orange Book listing in effect for the relevant FDA product. An issued patent does not automatically create FDA marketing exclusivity for the entire patent term.

Exclusivity category Relevance to crofelemer
Patent exclusivity Created by U.S. Patent 9,585,868 and any related patents
FDA new-drug exclusivity Separate from patent protection and generally shorter
Orphan-drug exclusivity Must be assessed separately from patent status
Orange Book listing Can support a Paragraph IV or Section viii process
Regulatory exclusivity Depends on the approved NDA and applicable FDA provisions

Mytesi was approved by the FDA in December 2012 for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS receiving antiretroviral therapy.[3] FDA approval does not itself establish that every later crofelemer use is patent-protected.

What is the Orange Book status of crofelemer and Mytesi?

The FDA Orange Book identifies patents submitted by an NDA holder for an approved drug. Orange Book status can change through patent-listing updates, expiration, delisting, or FDA administrative action.[2]

For a crofelemer generic applicant, the relevant regulatory questions are:

  • Whether U.S. Patent 9,585,868 is listed against the relevant Mytesi NDA
  • Whether the proposed generic label includes the patented HIV-associated diarrhea use
  • Whether the applicant files a Paragraph IV certification
  • Whether the applicant uses a Section viii statement to omit the patented indication
  • Whether the reference product has remaining regulatory exclusivity

A generic applicant that omits the patented indication may reduce induced-infringement exposure, but the risk depends on the proposed label, promotional conduct, prescribing patterns, and the scope of any remaining unexpired patents.

What Paragraph IV challenges could affect crofelemer?

A Paragraph IV certification would assert that an Orange Book-listed patent is invalid, unenforceable, or not infringed. For Patent 9,585,868, the most likely challenge theories would focus on the following issues.

Anticipation and obviousness

A challenger could rely on earlier crofelemer publications, clinical studies, patents, or regulatory materials showing:

  • Crofelemer use in HIV-positive patients
  • Treatment of antiretroviral-associated diarrhea
  • A 250 mg daily or 125 mg twice-daily regimen
  • Symptom improvement during treatment
  • Similar treatment durations

The key question would be whether the full claimed combination was disclosed in one reference for anticipation, or whether a skilled person would have found the claimed regimen obvious from the prior art.

Written description and enablement

The patent contains multiple duration ranges and symptom-response outcomes. A challenger could argue that the specification does not adequately support the full breadth of those ranges or every claimed clinical response.

Enablement risk would depend on whether the disclosure supports treatment across the full HIV-positive population, the claimed durations, and the claimed symptom categories without undue experimentation.

Indefiniteness

Potential pressure points include:

  • "About 250 mg"
  • "About 125 mg two times per day"
  • "Improvement begins on day 3"
  • "Improvement increases"
  • "Significant worsening of diarrhea"

Courts generally interpret "about" in view of the specification and technical context. The strength of an indefiniteness challenge would depend on the patent's disclosed tolerances, dosing data, and measurement methods.

Infringement proof

Method claims create a proof problem. A patent holder generally must establish that the accused product is used, directed, or induced to be used in the claimed manner. A product label that expressly recommends the claimed dose and indication can create substantial risk. A label that omits the patented use may reduce but not necessarily eliminate risk.

What formulations are protected by this patent?

Patent 9,585,868 does not expressly claim a particular formulation architecture in the claims provided. It claims administration of crofelemer at specified doses.

Accordingly, the patent may reach multiple dosage forms if they deliver the claimed crofelemer dose for the claimed HIV-associated diarrhea indication. It does not, based on the supplied claims, require:

  • A delayed-release tablet
  • A specific coating
  • A specific excipient
  • A particular dissolution profile
  • A specific manufacturing process
  • A particular particle size
  • A defined oral bioavailability

Separate crofelemer formulation, composition, botanical-extraction, or manufacturing patents could create additional barriers. Those rights must be analyzed independently from Patent 9,585,868.

How strong is the patent estate for crofelemer?

The estate is strongest where the commercial product, FDA label, and patent claim converge:

Risk area Assessment
HIV-associated diarrhea use High relevance
HAART-associated diarrhea use High relevance
250 mg daily dose High relevance
125 mg twice-daily dose High relevance
Chronic treatment Supported by multiple dependent claims
Stool-frequency endpoints Expressly covered
Stool-consistency endpoints Expressly covered
Fecal incontinence and urgency Covered in dependent claims
Non-HIV diarrhea Not covered by the supplied claims
Crofelemer molecule generally Not covered by the supplied claims
Manufacturing process Not covered by the supplied claims
Specific formulation technology Not apparent from the supplied claims

The patent is commercially stronger as a label and use patent than as a platform patent. Its value depends on whether a generic or competitor must market crofelemer for the HIV-associated diarrhea indication and whether the listed dose remains central to the product's clinical use.

Which companies are challenging crofelemer exclusivity?

A complete answer requires current FDA Orange Book records, ANDA Paragraph IV notices, PACER litigation records, and USPTO assignment and maintenance data. The claim text alone does not establish the identity of any challenger, settlement, or active infringement case.

No challenger, settlement agreement, or litigation outcome should be inferred solely from the existence of Patent 9,585,868. A Paragraph IV notice is confidential until litigation is filed or otherwise becomes public.

What generic launch risks exist for Mytesi?

A generic launch could follow several pathways:

Full-label challenge

The applicant includes the HIV-associated diarrhea use and certifies Paragraph IV against listed patents. This creates the clearest infringement dispute and could trigger Hatch-Waxman litigation and a 30-month stay under applicable conditions.[4]

Carved-out label

The applicant omits the patented indication through a Section viii statement or labeling carve-out. The commercial opportunity may be smaller if the HIV-associated diarrhea indication is the principal use protected by the patent.

Post-expiration launch

The applicant waits for patent expiration or settlement-authorized entry. This reduces litigation exposure but delays market access.

Dose or regimen distinction

A competitor could explore a materially different dosing regimen. That approach faces clinical, regulatory, and doctrine-of-equivalents risks and may not be commercially attractive if the approved regimen is the standard of care.

Does crofelemer face biosimilar risk?

No. Crofelemer is a botanical-derived small-molecule drug product, not a biologic subject to the biosimilar pathway under the Public Health Service Act. Competitive entry would generally involve an ANDA, a 505(b)(2) application, or a full NDA depending on the product's formulation, clinical reliance, and differences from Mytesi.[3][5]

The main regulatory competition is therefore generic or follow-on small-molecule competition, not biosimilar substitution.

What litigation and settlement issues matter?

The critical litigation issues are:

  1. Whether the patent is listed for the relevant crofelemer NDA.
  2. Whether a generic label includes the patented indication.
  3. Whether a Paragraph IV notice has been served.
  4. Whether the NDA holder filed an infringement action within the statutory period.
  5. Whether a 30-month stay applies.
  6. Whether the parties entered an authorized generic or delayed-entry settlement.
  7. Whether other crofelemer patents create independent barriers.

A settlement could permit entry before patent expiration, but its commercial effect would depend on the entry date, product restrictions, authorized-generic terms, and any Federal Trade Commission review.

How does Patent 9,585,868 compare with broader drug patents?

Patent type Typical scope Position of 9,585,868
Composition patent Covers the active molecule Not a composition claim
Formulation patent Covers dosage form or delivery system Not apparent from supplied claims
Manufacturing patent Covers production or extraction Not a manufacturing claim
Method-of-use patent Covers treating a disease with the drug Yes
Patient-selection patent Covers a defined patient subgroup Yes, especially HIV-positive patients and prior protease-inhibitor users
Dose-regimen patent Covers amount and frequency Yes
Outcome patent Covers defined treatment response Yes, in dependent claims

The patent's claim breadth is concentrated rather than general. It can materially delay an HIV-diarrhea generic while leaving other crofelemer indications and noninfringing development programs open.

Key Takeaways

  • U.S. Patent 9,585,868 is a crofelemer method-of-treatment patent.
  • Claim 1 requires an HIV-positive subject, HIV- or HAART-associated diarrhea, and approximately 250 mg daily or 125 mg twice daily.
  • The patent does not broadly claim crofelemer, all diarrhea indications, or a specific formulation based on the supplied claims.
  • Dependent claims cover treatment duration, day-3 response, chronic administration, stool consistency, stool frequency, urgency, and fecal incontinence.
  • Claim 20 focuses on HIV-positive patients with prior protease-inhibitor use.
  • The expected patent term extends into 2029, subject to the official USPTO term calculation and any applicable adjustments.
  • Generic entry risk depends heavily on Orange Book listing status, label design, Paragraph IV strategy, and other crofelemer patents.
  • Crofelemer is not subject to biosimilar competition; follow-on entry would use small-molecule regulatory pathways.
  • The patent is strongest as a use and dosing barrier for the Mytesi HIV-associated diarrhea indication.

FAQs About U.S. Patent 9,585,868

Is Patent 9,585,868 a patent on Mytesi itself?

No. It is a method patent covering specified use of crofelemer in HIV-positive patients with HIV-associated or HAART-associated diarrhea.

Does the patent cover crofelemer for irritable bowel syndrome?

Not based on the supplied claims. The claims require an HIV-positive patient and HIV-associated or HAART-associated diarrhea.

Can a generic use a different crofelemer dose?

A materially different dose may avoid literal infringement of claim 1, but regulatory approval, clinical efficacy, and potential equivalents issues remain relevant.

Does prior protease-inhibitor use apply to every claim?

No. It is expressly required by claim 20. Claim 1 does not include that prior-use limitation.

Is a crofelemer generic automatically blocked until 2029?

No. Market entry depends on the complete Orange Book listing, other relevant patents, the generic label, any Paragraph IV litigation, settlements, and the applicable expiration dates.

References

  1. U.S. Patent No. 9,585,868, Methods of treating HIV-associated diarrhea (Mar. 7, 2017). U.S. Patent and Trademark Office.
  2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.
  3. U.S. Food and Drug Administration. (2012). Mytesi (crofelemer) prescribing information. Napo Pharmaceuticals, Inc.
  4. Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).
  5. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355; Public Health Service Act, 42 U.S.C. § 262.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 9,585,868

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Napo Pharms Inc MYTESI crofelemer TABLET, DELAYED RELEASE;ORAL 202292-001 Dec 31, 2012 RX Yes Yes ⤷  Start Trial ⤷  Start Trial SYMPTOMATIC RELIEF OF NON-INFECTIOUS DIARRHEA ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,585,868

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2011320155 ⤷  Start Trial
Brazil 112013010774 ⤷  Start Trial
Canada 2816416 ⤷  Start Trial
China 103370101 ⤷  Start Trial
China 107595836 ⤷  Start Trial
Colombia 6771411 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.